What Analysts Are Recommending for ELAN and ZTS in February

Stock price movements

On February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and 22.47% below its 52-week high of $37.61. Its market capitalization was $10.63 billion, and its trailing-12-month and forward PE ratios are 123.76x and 22.79x, respectively.

Since its fourth-quarter earnings release on February 6, Elanco Animal Health stock has dropped by 3.51% from $30.22 on February 5 to $29.16 on February 19. The company missed consensus revenue estimates by $4.74 million but surpassed the consensus EPS estimate by $0.01 in the fourth quarter.

What Analysts Are Recommending for ELAN and ZTS in February

On February 19, Zoetis (ZTS) closed at $94.91, 0.48% higher than its previous closing price, 23.26% higher than its 52-week low of $77.00, and 1.72% below its 52-week high of $96.57. Its market capitalization was $45.36 billion, and its trailing-12-month and forward PE ratios are 33.24x and 24.42x, respectively.

Since its fourth-quarter earnings release on February 14, Zoetis stock has declined by 0.88% from $29.42 on February 13 to $29.16 on February 19. The company surpassed both of its consensus revenue and consensus EPS estimates by $30 million and $0.02, respectively. Zoetis is trading at a lower trailing PE ratio but higher forward PE ratios as compared to Elanco Animal Health.

Analysts’ recommendations and target price

The 12-month consensus recommendations for Elanco Animal Health and Zoetis are a “buy.” Of the 13 analysts covering Elanco Animal Health, two recommend a “strong buy,” four recommend a “buy,” six recommend a “hold,” and one analyst recommends a “sell.” Their 12-month target price is $34.7, 19.00% higher than its last closing price on February 20. The highest target price estimate for the company is $38, and the lowest is $29.

Of the 15 analysts covering Zoetis, five recommend a “strong buy,” six recommend a “buy,” and four recommend a “hold.” Their 12-month target price is $100.09, 5.46% higher than its last closing price on February 20. The highest target price estimate for the company is $113, and the lowest is $86.

Next, we’ll look at the revenue growth trajectory of Elanco Animal Health and Zoetis in greater detail.